Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
/in Colorectal Cancer, Dendritic Cells, International PublicationsDeep hyperthermia with radiofrequencies in patients with liver metastases from colorectal cancer
/in Colorectal Cancer, Hyperthermia, International PublicationsA Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
/in Breast Cancer, Colorectal Cancer, Dendritic Cells, International Publications, Ovarian Cancer, Pancreatic CancerCharacterization of mild whole-body hyperthermia protocols using human breast, ovarian, and colon tumors grown in severe combined immunodeficient mice
/in Colorectal Cancer, Hyperthermia, International PublicationsInduction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
/in Colorectal Cancer, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer